About Absea Biotechnology
Founded in 2020, Absea Biotechnology Ltd. develops recombinant proteins, monoclonal antibodies and protein engineering technologies for life science research and biopharmaceutical applications. The company focuses on high-throughput protein and antibody development, supporting large-scale proteomics, interactomics and target discovery programmes. Its proprietary platform enables the rapid generation and characterisation of soluble proteins and antibodies, helping researchers investigate protein function, molecular interactions and disease mechanisms. Through collaborations with academic and industrial partners, Absea has built an extensive library of recombinant proteins covering a substantial proportion of the human proteome, supporting applications in basic research, diagnostics, drug discovery and AI-driven protein design.
Absea’s portfolio includes recombinant proteins, monoclonal antibodies and custom development services designed for proteomics, interactomics and therapeutic research workflows. The company combines protein expression, engineering and validation capabilities to deliver reagents suitable for biomarker discovery, assay development, target validation and translational research. In addition, Absea provides technology solutions that enable large-scale protein interaction studies and the generation of new protein and antibody assets for research and commercial applications.
Europa Biosite subsidiaries distribute Absea products in Austria, Belgium, Denmark, Estonia, Finland, Germany, Iceland, Ireland, Latvia, Lithuania, Luxemburg, Netherlands, Norway, Sweden, Switzerland and the United Kingdom.